IP Library › Granted Patent US 12,357,679
Granted Patent B2
US 12,357,679 · App. 18/143,368 · Granted Jul 15, 2025

Albumin-based non-covalent complexes and methods of use thereof

Inventors: Ravi Verma (Monrovia, CA); Changjun Yu (Pasadena, CA)
Assignee: Spectral Platforms, Inc.
A61K38/385A01N43/90A61K9/00C12Q1/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,679
App. No.
18/143,368
Granted
Jul 15, 2025
Kind
B2
Abstract

A non-covalent complex of an albumin molecule and a hydrophobic ligand, compositions containing the same, and methods of use thereof are provided. The present complex may find use in delivering the hydrophobic ligand to microorganisms that have albumin-binding outer surfaces, such as a cell wall.

Claims (26)

1. A method for determining antimicrobial susceptibility of a microorganism for an antimicrobial, the method comprising:

contacting a composition comprising a microorganism comprising a cell wall with the antimicrobial;

contacting the composition comprising the microorganism and the antimicrobial with an aqueous solution comprising a non-covalent complex of a hydrophobic molecule and a single albumin protein, wherein the hydrophobic molecule functionally associates with the microorganism;

detecting one or more properties of the hydrophobic molecule in the composition; and

determining the antimicrobial susceptibility of the microorganism for the antimicrobial based on the detected property of the hydrophobic molecule.

2. The method of claim 1 , wherein the microorganism is a pathogenic microorganism.

3. The method of claim 1 , wherein contacting of the composition comprising the microorganism with the antimicrobial occurs in vitro.

4. The method of claim 1 , wherein the hydrophobic molecule is a carotenoid.

5. The method of claim 4 , wherein the carotenoid is a carotene.

6. The method of claim 5 , wherein the carotene is lycopene or β-carotene.

7. The method of claim 1 , wherein the antimicrobial is an antibacterial.

8. The method of claim 1 , wherein the antimicrobial is an antifungal.

9. The method of claim 1 , wherein the albumin protein is a human serum albumin protein.

10. The method of claim 1 , wherein the method further comprises forming the aqueous solution comprising the non-covalent complex of hydrophobic molecule and single albumin protein by:

dissolving the hydrophobic molecule in:

i) a first organic solvent comprising a C 3 -C 5 ketone; or

ii) a combination of the first organic solvent and a second organic solvent in a ratio of from about 0.001:1 to about 1000:1 v/V, to provide a first solution;

combining the first solution with a second solution to provide a third solution, wherein the second solution is an aqueous solution comprising an albumin protein; and

removing the first organic solvent or the combination of the first organic solvent and the second organic solvent from the third solution to provide a fourth solution, wherein the fourth solution is an aqueous solution comprising a non-covalent complex of the hydrophobic molecule and a single albumin protein.

11. The method of claim 10 , wherein the C 3 -C 5 ketone is acetone.

12. The method of claim 10 , wherein the hydrophobic molecule is dissolved in the combination of a first organic solvent and a second organic solvent, and wherein the ratio of the first organic solvent and the second organic solvent is in the range of about 1:1 to about 5:1.

13. The method of claim 12 , wherein the hydrophobic molecule is dissolved in the combination, and wherein the combination comprises the first organic solvent and the second organic solvent in a ratio of about 2:1.

14. The method of claim 10 , wherein the hydrophobic molecule is dissolved in the combination, and wherein the method comprises:

dissolving the hydrophobic molecule in the second organic solvent, to provide a fifth solution; and

combining the fifth solution with the C 3 -C 5 ketone to provide the first solution prior to combining the first solution with the second solution.

15. The method of claim 10 , wherein the removing is performed by evaporation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2023
From: VERMA, RAVI; YU, CHANGJUN
To: SPECTRAL PLATFORMS, INC.
Reel/Frame 064235/0205 →
Continuity (7)
Division 17154251 · Jan 21, 2021
Division 16422704 · May 24, 2019
Division 16056366 · Aug 6, 2018
Division 15148587 · May 6, 2016
Provisional Application 62294931 · Feb 12, 2016
Provisional Application 62158670 · May 8, 2015
Related Publication 20240075107A1 · Mar 7, 2024
References Cited (96)
US 4145343A · Rodriguez et al. · 1979 [cited by applicant]
US 4187285A · Meeks et al. · 1980 [cited by applicant]
US 4226846A · Saklad · 1980 [cited by applicant]
US 5082771A · Detty · 1992 [cited by applicant]
US 5134126A · Hector et al. · 1992 [cited by applicant]
US 5301125A · Chimenti et al. · 1994 [cited by applicant]
US 5364766A · Mach et al. · 1994 [cited by applicant]
US 5439801A · Jackson · 1995 [cited by applicant]
US 5464755A · Bochner · 1995 [cited by applicant]
US 5895751A · Hattori et al. · 1999 [cited by applicant]
US 5916596A · Desai et al. · 1999 [cited by applicant]
US 6040906A · Harhay · 2000 [cited by applicant]
US 6617149B2 · Restaino · 2003 [cited by applicant]
US 6750006B2 · Powers et al. · 2004 [cited by applicant]
US 8252522B2 · Vullev et al. · 2012 [cited by applicant]
US 8450079B2 · Kovalenko et al. · 2013 [cited by applicant]
US 8835185B2 · Nishiuma et al. · 2014 [cited by applicant]
US 10342855B2 · Verma et al. · 2019 [cited by applicant]
US 10533207B2 · Jung et al. · 2020 [cited by applicant]
US 10940183B2 · Verma et al. · 2021 [cited by applicant]
US 11105747B2 · Verma et al. · 2021 [cited by applicant]
US 20020097376A1 · Applegate et al. · 2002 [cited by applicant]
US 20040014655A1 · Hegedus et al. · 2004 [cited by applicant]
US 20050004011A1 · Cavaleri et al. · 2005 [cited by applicant]
US 20050009788A1 · Lockwood et al. · 2005 [cited by applicant]
US 20050064028A1 · Hegedus et al. · 2005 [cited by applicant]
US 20050075337A1 · Lockwood et al. · 2005 [cited by applicant]
US 20050089901A1 · Porter et al. · 2005 [cited by applicant]
US 20070232536A1 · Hegedus et al. · 2007 [cited by applicant]
US 20080077351A1 · Tischler et al. · 2008 [cited by applicant]
US 20080220989A1 · Tseng et al. · 2008 [cited by applicant]
US 20100143883A1 · Wilson et al. · 2010 [cited by applicant]
US 20130052636A1 · Verma et al. · 2013 [cited by applicant]
US 20140081133A1 · Nie et al. · 2014 [cited by applicant]
US 20150309040A1 · Chang et al. · 2015 [cited by applicant]
US 20160122698A1 · Suslick et al. · 2016 [cited by applicant]
US 20160299135A1 · Cameron et al. · 2016 [cited by applicant]
US 20160324933A1 · Verma et al. · 2016 [cited by applicant]
US 20170191020A1 · Recht et al. · 2017 [cited by applicant]
US 20170219622A1 · Yang et al. · 2017 [cited by applicant]
US 20180292324A1 · Verma et al. · 2018 [cited by applicant]
US 20210290734A1 · Verma et al. · 2021 [cited by applicant]
EP 0326618 · 1989 [cited by applicant]
EP 1711823 · 2006 [cited by applicant]
EP 2359859 · 2011 [cited by applicant]
JP S63297664 · 1988 [cited by applicant]
JP H03272440 · 1991 [cited by applicant]
JP 2004163422 · 2004 [cited by applicant]
JP 2007532982 · 2007 [cited by applicant]
JP 2009254386 · 2009 [cited by applicant]
JP 2010233503 · 2010 [cited by applicant]
JP 2013517490 · 2013 [cited by applicant]
WO WO1998014174 · 1998 [cited by applicant]
WO WO1999013914 · 1999 [cited by applicant]
WO WO2003106699 · 2003 [cited by applicant]
WO WO2004011423 · 2004 [cited by applicant]
WO WO2005066612 · 2005 [cited by applicant]
WO WO2007078635 · 2007 [cited by applicant]
WO WO2009018544 · 2009 [cited by applicant]
WO WO2015021300 · 2015 [cited by applicant]
WO WO2017020000 · 2017 [cited by applicant]
WO WO2018175346 · 2018 [cited by applicant]
WO WO2018183675 · 2018 [cited by applicant]
Baron (Medical Microbiology 4 edition, Galveston TX, University of Texas Medical Branch at Galveston, Chapter 6, 1996, pp. 1-10) (Year: 1996). [cited by examiner]
Chan and Chen (2012) “Human Serum Albumin Stabilized Gold Nanoclusters as Selective Luminescent Probes for Staphylococcus aureus and Methicillin-Resistant Staphylococcus aureus”; Anal. Chem. 84; pp. 8952-8956. [cited by applicant]
Xie, et al (2009) “Protein-Directed Synthesis of Highly Fluorescent Gold Nanoclusters”; J. Am. Chem. Soc. 131; pp. 888-889. [cited by applicant]
BioNavis Ltd.; “Interactions of small molecular weight drugs with human serum albumin”; Application Note # 121. 2 pages; downloaded off the web Jun. 17, 2015. [cited by applicant]
Davis, Charles Patrick; [cited by applicant]
Fasano Mauro, et al.; (2005) The Extraordinary Ligand Binding Properties of Human Serum Albumin; IUBMB Life. 57(12): pp. 787-796. [cited by applicant]
Gaillot, et al. (2000) “Evaluation of CHROMagar Staph. aureus, a new chromogenic medium, for isolation and presumptive identification of [cited by applicant]
Gülseren Ibrahim, et al; (2007) “Structural and functional changes in ultrasonicated bovine serum albumin solutions”; Ultrasonics Sonochemistry 14; pp. 173-183. [cited by applicant]
Henmi, et al (1989) “Astaxanthin and/or Canthaxanthin-actomyosin Complex in Salmon Muscle”; [cited by applicant]
Hoskins (1984) “Resonance Raman Spectroscopy of ß-Carotene and lycopene”; Journal of Chemical Education 61, No. 5; pp. 460-462. [cited by applicant]
Jehlička, et al (2014) “Potential and Limits of Raman Spectroscopy for Carotenoid Detection in Microorganisms: Implications for Astrobiology”; [cited by applicant]
Khana Salman, et al (2015) “Improved efficiency and stability of secnidazole—An ideal delivery system”; Saudi J Biol Sci.22(1); pp. 42-49. [cited by applicant]
Li, et al (2015) “ß-Carotene and Astaxanthin With Human and Bovine Serum Albumins”; Food Chem 179; pp. 213-221. [cited by applicant]
Lieber and Mahadevan-Jensen (2003) “Automated Method for Subtraction of Fluorescence from Biological Raman Spectra”; [cited by applicant]
López-Ramírez, et al.(2010) “Trans-cis isomerisation of the carotenoid lycopene upon complexation with cholesteric polyester carriers investigated by Raman spectroscopy and density functional theory”; Journal of Raman S… [cited by applicant]
Merlin, Jean Claude (1985) “Resonance Raman spectroscopy of carotenoids and carotenoid-containing systems”; Pure and Applied Chemistry 57(5); pp. 785-792. [cited by applicant]
Militello, Valeria, et al.(2004) “Aggregation kinetics of bovine serum albumin studied by FTIR spectroscopy and light scattering”; Biophysical Chemistry 107; pp. 175-187. [cited by applicant]
Paál, Krisztina, et al; (2001) “High affinity binding of paclitaxel to human serum albumin”; Eur. J. Biochem. 268; pp. 2187-2191. [cited by applicant]
Partali et al. (1985) “Carotenoids in food chain studies—I. Zooplankton (Daphnia magna) response to a unialgal (Scenedesmus acutus) carotenoid diet, to spinach, and to yeast diets supplemented with individual carotenoid… [cited by applicant]
Penzkofer, et al. (2007) “Protein aggregation studied by forward light scattering and light transmission analysis”; Chemical Physics 342(1-3); pp. 55-63. [cited by applicant]
Penzkofer, et al. (2016) “Absorption and emission spectroscopic investigation of thermal dynamics and photo-dynamics of the rhodopsin domain of the rhodopsin-guanylyl cyclase from the aquatic fungus Blastocladiella emer… [cited by applicant]
Rehman and Khan (2015) “Understanding the interaction between human serum albumin and anti-bacterial/anti-cancer compounds”; Curr Pharm Des. 21(14); pp. 1785-1799. [cited by applicant]
Rodríguez, Galdón B, et al; (2013) “Spectroscopic study of the interaction between lycopene and bovine serum albumin”; Luminescence. 28(5); pp. 765-770. [cited by applicant]
Sivertsen, Annfrid, et al; (2014) “Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin”; BMC Struct Biol. 14/4; doi: 10.1186/1472-6807-14/4; pp. 1-14. [cited by applicant]
Tang K, et al; (2005) “Interaction of daunomycin antibiotic with human serum albumin: investigation by resonant mirror biosensor technique, fluorescence spectroscopy and molecular modeling methods”; J Pharm Biomed Anal.… [cited by applicant]
Varshney A, et al; (2010) “Ligand binding strategies of human serum albumin: how can the cargo be utilized?”; Chirality. 22(1); pp. 77-87. [cited by applicant]
Wang, Rongsheng E, et al; (2012) “A Homogeneous Fluorescent Sensor for Human Serum Albumin”; J Pharm Biomed Anal. 63; pp. 165-169. [cited by applicant]
Yang F, et al; (2014) “Interactive association of drugs binding to human serum albumin”; Int J Mol Sci.15(3); pp. 3580-3595. [cited by applicant]
Zhong Dongping, et al; (2000) “Femtosecond studies of protein-ligand hydrophobic binding and dynamics: human serum albumin”; Proc Natl Acad Sci U S A. 97(26); pp. 14056-14061. [cited by applicant]
Arkin, et al(1990) “Applications of Imaging Spectroscopy in Molecular Biology II. Colony Screening Based on Absorption Spectra”; [cited by applicant]
Foster, et al (1982) “Monoclonal antibodies selective for the functional states of bovine factor V and factor Va”; [cited by applicant]
Rossomando, Edward F. (1970) “*Studies on the structural polarity of bacteriophage f1”; Virology vol. 42, Issue 3; pp. 681-687. [cited by applicant]
Yang Wenjing, et al (2016) “Low-fouling electrospun PLLA films modified with zwitterionic poly(sulfobetaine methacrylate)-catechol conjugates”; [cited by applicant]